The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 30, 2016

Filed:

Sep. 23, 2013
Applicant:

Ohio State Innovation Foundation, Columbus, OH (US);

Inventors:

Carlo M. Croce, Columbus, OH (US);

Giulia Romano, Columbus, OH (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/85 (2006.01); A61K 38/19 (2006.01); A61K 38/17 (2006.01); C12Q 1/68 (2006.01); C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); A61K 31/7105 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 38/19 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 38/1761 (2013.01); A61K 45/06 (2013.01); C12N 15/1135 (2013.01); C12Q 1/6886 (2013.01); G01N 33/574 (2013.01); G01N 33/6863 (2013.01); C12N 2310/113 (2013.01); C12N 2310/14 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); C12Q 2600/178 (2013.01); G01N 2800/52 (2013.01);
Abstract

Methods and compositions for inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof, comprising administering an effective amount of an anti-miR-494 nucleic acid construct sufficient to target one or more tumor suppressor genes (TSGs) are described. Activation of the ERK1/2 pathway is a major determinant of diverse cellular processes and cancer development and is responsible for the transcription of several important miRNAs. Described herein is a link between the ERK1/2 pathway and BIM expression through miR-494. This ERK1/2 pathway regulates apoptosis and cell proliferation through miR-494 and mechanisms responsible for TRAIL resistance. Materials and methods related to the study and treatment of cancer are described.


Find Patent Forward Citations

Loading…